Double Bond Pharmaceutical (DBP) Q4 2025 earnings summary

Executive summary

• 2025 marked a breakthrough year with significant progress in SI053/Temodex development, focusing on glioblastoma treatment and expanding clinical applications to recurrent GBM.

• Strategic collaborations and promising clinical data have strengthened confidence in the product's market potential.

• Efforts are underway to commercialize Temodex outside Eastern Europe and integrate AI tools in research.

Financial highlights

• Total group revenues for 2025 were SEK 0.1 million, down from SEK 1.1 million year-over-year.

• Operating loss for the year was SEK -1.7 million, compared to SEK -1.6 million in 2024.

• Net result for the year improved to SEK -0.3 million from SEK -7.1 million year-over-year.

• Earnings per share for 2025 were SEK -0.0, compared to SEK -0.06 in 2024.

• Cash and cash equivalents at year-end were SEK 1.1 million, down from SEK 3.9 million at the end of 2024.

Outlook and guidance

• Existing liquidity and proceeds from the recent share issue are expected to fund operations through Q4 2026.

• Future financing is anticipated from EU grants, product licensing, and potential new share issues.

• No dividend is proposed for 2025, with ambitions to provide dividends in the future.